NoToVir is a new biotech Start-up established on December 2017, active in the field of medical biotechnology. NoToVir arises from the experience and work carried out over the years by the Laboratory of Pathogenesis of Viral Infections – Department of Public Health and Pediatrics, University of Turin (UniTo), in collaboration with the Laboratory of Virology, Department of Translational Medicine, University of Eastern Piedmont (UPO), Novara, Italy. The company’s main objective is the screening of innovative antiviral molecules for the production of new pharmacologically selectively active principles against viral infections.
The current development lines are related to Herpesvirus infections, and in particular on the treatment of congenital cytomegalovirus (cHCMV) infections or cytomegalovirus infections in transplanted immunosuppressed individuals. Conditions whose state of the art therapy and available treatments are still largely unsatisfied, considering the wide prevalence of pathologies and the significant side effects of non-specific and off-label experimental drugs in use.
The first two patents rely on a new mechanism of action against Herpesvirus, addressed to block the chemical modifications (biosynthesis) of the proteins that these viruses require to regulate their replication. It is important to consider that no drugs have been developed so far that block post-translational modifications (PTM) specifically activated by any virus, and therefore the proposed approach is absolutely novel and can be developed over a wide range of development pipelines.
The team highlighted for the first time the role of a specific PTM, known as citrullination (i.e. the non-physiological transformation of the arginine contained in cellular proteins into citrulline) during viral infections.
- Antiviral therapy against congenital viral infections
- Antiviral therapy against DNA viruses
- Clinical applications
Based on recent data, a global overview of the current market value of drugs used for the therapy of HCMV infections can be drawn, as detailed in the recently published report “Cytomegalovirus (CMV) Infections – Pipeline Assessment and Market Forecasts to 2019 “(GlobalData, 2013).
USD millions - Estimated prophylactic market for HCMV in 2013
USD millions - Expected growth in 2022 (CAGR of 7.79%)
USD millions - Estimated HCMV therapeutic market
USD millions - Expected growth in 2022 (CAGR of 3.51%)